All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the MPN Hub was pleased to speak to Bhagirathbhai Dholaria, Vanderbilt University Medical Center, Nashville, US. We asked, What is the role of transplant in CNL? What are the key considerations about timing of transplant in CNL?
What is the role of transplant in CNL? Key considerations about timing of transplant in CNL
Dholaria begins by discussing the difficulties in obtaining data on the effectiveness of allogeneic transplants in patients with CNL. Dholaria goes on to speak about a large-scale observational study, combining data from the CIBMTR and European transplant registry, and gives an insight into disease-free and overall survival in CNL. Finally, Dholaria touches on the role of pre-transplant therapies, such as ruxolitinib, in improving patient outcomes.
Fedratinib in myelofibrosis
Fedratinib is a pyrimidine-based Janus kinase 2 (JAK2) inhibitor currently licenced by the U.S. Food and Drug Administration (FDA) for the treatment of adults with intermediate-2 or high-risk primary or secondary...
Can navitoclax plus ruxolitinib induce clinically relevant responses in patients with myelofibrosis?
The MPN Hub were pleased to speak to Jacqueline S. Garcia, Dana-Farber Cancer Institute, Boston, US, during the 61st American Society of Hematology...
Subscribe to get the best content related to MPN delivered to your inbox